Trikafta—known as Kaftrio in Europe—itself has contributed $7.5 billion during the first nine months of 2024. But investors’ attention has lately shifted to suzetrigine, a nonaddictive pain ...

Vertex Earnings: Robust Sales of Trikafta/Kaftrio Support Long-Term Growth and Diverse Pipeline Narrow-moat Vertex delivered solid third-quarter results, highlighted by a 12% increase in product ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

Vertex currently markets four cystic fibrosis (CF) products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Revenues in fourth-quarter 2023 are likely to have ...

Nearly 93% of the company's sales come from its cystic fibrosis (CF) drug Trikafta/Kaftrio -- for now. The big biotech company is usually highly profitable. For example, Vertex reported earnings ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta (Kaftrio in Europe), which is required to be administered twice daily.

Total revenues rose 12% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe) in younger age groups. The company currently markets four CF products ...

Kaftrio will be available in the coming weeks for patients Cystic fibrosis patients in Northern Ireland will be able to access the drug Kaftrio for treatments through the health service. The ...

In draft guidance, National Institute for Health and Care Excellence (NICE) experts have said Kaftrio costs too much to be offered on the NHS. A four-week consultation will decide whether it ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

The figure beat the Zacks Consensus Estimate of $2.67 billion. Total revenues rose 12% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe) in younger ...